{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:54:24Z","timestamp":1794002064877,"version":"4.8.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014620","name":"Micropalaeontological Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.annonc.2025.09.139","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:06:22Z","timestamp":1760702782000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274"],"prefix":"10.1016","volume":"37","author":[{"given":"M.D.","family":"Galsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.P.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lebret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-9326","authenticated-orcid":false,"given":"S.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-6136","authenticated-orcid":false,"given":"M.","family":"Agerbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Stenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chhibber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.F.","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.09.139_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103683","article-title":"Recent therapeutic advances in urothelial carcinoma: a paradigm shift in disease management","volume":"174","author":"Bellmunt","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.139_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/cancers15030566","article-title":"Current and future landscape of perioperative treatment for muscle-invasive bladder cancer","volume":"15","author":"Esteban-Villarrubia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2025.09.139_bib3","first-page":"246","volume":"5","author":"Kim","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2025.09.139_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/17562872211029779","article-title":"Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?","volume":"13","author":"Renner","year":"2021","journal-title":"Ther Adv Urol"},{"issue":"22","key":"10.1016\/j.annonc.2025.09.139_bib5","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.139_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.139_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12935-025-03707-z","article-title":"Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"25","author":"Gao","year":"2025","journal-title":"Cancer Cell Int"},{"issue":"7","key":"10.1016\/j.annonc.2025.09.139_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14737140.2025.2512036","article-title":"The use of ctDNA for muscle-invasive bladder cancer before and after radical cystectomy","volume":"25","author":"Manolitsis","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.139_bib9","first-page":"183","article-title":"Perioperative use of ctDNA to guide treatment for urothelial carcinoma: the future is now","volume":"10","author":"Stewart","year":"2024","journal-title":"Bladder Cancer"},{"issue":"7867","key":"10.1016\/j.annonc.2025.09.139_bib10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.139_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-471912","article-title":"Current and future role of circulating DNA in the diagnosis and management of urothelial carcinoma","volume":"45","author":"Bellmunt","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.139_bib12","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1097\/JS9.0000000000001372","article-title":"Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis","volume":"110","author":"Liu","year":"2024","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.139_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.annonc.2025.09.139_bib14","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial","volume":"43","author":"Felip","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.09.139_bib15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.09.139_bib16","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.139_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.139_bib18","series-title":"Codes and coverages","year":"2025"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2025.09.139_bib19","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2021.39.15_suppl.2575","article-title":"CheckMate 8KX: phase 1\/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (\u00b1 rHuPH20)","volume":"39","author":"Lonardi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.139_bib20","first-page":"524","article-title":"Novel model-based approach to support clinical pharmacology profiling of subcutaneous nivolumab in renal-cell carcinoma and bridging to alternative SC dosing regimens and solid tumor indications","volume":"12","author":"Zhao","year":"2024","journal-title":"J Immunotherap Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.139_bib22","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:55:25Z","timestamp":1773906925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425049300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0923753425049300"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.139","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}